公司資料
Theravance Biopharma 股價、新聞與催化劑
- 股票代碼:
- TBPH
- 交易所:
- NASDAQ
- 產業:
- Biopharma
- 所在地:
- United States
股票表現
16.92 USD (-0.29%)
收盤價
最後更新: 2026年8月17日
803M USD
市值
股價為何變動
As of Aug 17, 2026, TBPH closed down 0.29% at $16.92. No new same-company headline was identified in the current news window.
公司概覽
Respiratory Medicines
Theravance Biopharma is a biopharmaceutical company whose principal economic asset is a respiratory medicine commercialized through a collaboration.
YUPELRI
YUPELRI, or revefenacin, is a once-daily nebulized long-acting muscarinic antagonist for maintenance treatment of chronic obstructive pulmonary disease. Theravance receives collaboration revenue tied to U.S. sales. Following the outcome of the CYPRESS study, the company is winding down that clinical program and restructuring around its commercial asset and remaining strategic opportunities.
未來催化劑
近期新聞
- 01
- 02
- 03
- 04
- 05
相似股票
商業成熟度、治療領域或催化劑模式相近的同業公司。